NASH: Evolution of a multi-billion-dollar Market

Until previous decade, most of the global population remained averse to digging out the exact root of certain diseases that had no visible effect. Overlooking these, resulted in grave consequences at times; some even leading to death. However, in modern scenario technology has influenced drastic change in the manner of disease diagnostics and the way we perceive uncommon syndromes has changed drastically. Technology has matured enough over the years to explore explanations to complicated challenges in the human body. As a result of years of practice and study in biomarker technologies, it would prove to be promising breakthrough in the diagnosis of Nonalcoholic Steatohepatitis (NASH), more commonly known as the ‘silent’ liver disease. 

NASH is a type of fatty liver disease occurs in humans whose alcohol intake is low or absent. However, the condition highly imitates the symptoms of alcoholic liver dysfunction. The disease silently creeps in the system, with little or no effect on other body functions. However, in due course of time it can possibly disrupt the entire working of the liver and render it useless. In severe case of cirrhosis, it might to lead to high blood pressure with extreme levels of bile and poisonous toxins. The conditional crisis could potentially end up in a cancerous state. 

Global environment in NASH market 
An extensive market analysis of the NASH market has been in the recently published by Allied Market Research (AMR) in a report about the global nonalcoholic steatohepatitis market. The report forecasts the overall market size to reach $1.6 billion worth by the end of 2020. Over the course of forecast period ranging from 2014 to 2020, the industry is expected to grow at a CAGR of 25.6%. North America shares about half of the global market share at present. Europe ranks second after North America in terms of revenue generation despite high research and development activities for innovating novice diagnostic techniques. Post-trial commercialization of these innovations are restricted by local governmental regulations.

Obesity is accounted as being the primary reason for causing NASH in global population. A general average of approximately 5% of Americans are believed to be affected from the condition. Prediabetes, or Type 2 diabetes, is another among the main causes for NASH, and eventually a key reason for the growth of Nonalcoholic Steatohepatitis / NASH market on global scale. The research states the number of diabetes patients would step up to 552 million by 2030 worldwide. 

For more information visit at: https://www.alliedmarketresearch.com/nonalcoholic-steatohepatitis-NASH-market

“The rampant growth in incidences of diabetes and obesity has prompted pharmaceutical manufacturers to seek out novel pharmaceutical solutions to tap promising potential in NASH,” states AMR analyst Roshan Deshmukh. "Instrumental initiatives and increasing clinical trials for the development of novel NASH therapeutics will result in faster commercialization," adds the analyst.

Therapeutic arrangements in NASH market

Generally suggested recovery measures are the elementary requirements of maintaining a good health. Experts suggest following a balanced diet that does not include alcohol or unnecessary drug intake. Nevertheless, medications remain essential considering the damage that has already been caused. Enhanced biomarker technologies to diagnose liver disorders work positively for the overall growth of market. Major industry participants have created a leverage over the past shortcoming relating to non-availability of therapeutic solutions with their advanced drug offerings. Treatment drugs should essentially perform pharmacological activities that immediately improve insulin sensitivity, glucose breakdown, and dyslipidemia. Since they should also effectually retard fat deposition in liver in order to pause fibrosis, they are expected to have anti-inflammatory and anti-oxidant properties.

Kenneth Cusi, researcher at the University of Florida Health, led a three-year clinical trial involving 101 NASH patients diagnosed with prediabetes or Type 2 diabetes. It was realized during his study, that pioglitazone intake reduced fatty liver disease activity in 58 percent of the cases. So much so, around 51% of these patients no longer exhibited any indications of liver risks after the course of trials.

“The exciting thing is that there is a generic drug that already prevents the onset of Type 2 diabetes and cardiovascular disease in recent studies. Now, it can reduce disease from excess liver fat accumulation and liver inflammation, and halt fibrosis that leads to cirrhosis. This will have a lot of long-term benefits for many people with a medication that will be very affordable and is already being used to treat Type 2 diabetes,” Cusi said. However, the researcher also observed that the results are based on a single-center study, and should be performed for a much larger and diverse group of patients to affirm its approval.

Industry prospects for investors
Stringent government regulations, as discussed in the case of European region, works against speedy introduction of therapeutic arrangements. Patients suffer the consequences of delayed diagnosis and overdue medical care. Lack of information about the pathophysiology of NASH tissue is an issue that heavily concerns the drug developers. Some of the key companies in the NASH market are Genfit, Gilead Science, Novo Nordisk, Intercepts Pharmaceuticals, Enzo Biochem, Inc. and Raptor Pharmaceutical Corp. These work strenuously towards successful commercial placement of their drug offerings in the market. As an immediate effect of commercialization of the NASH therapeutics, healthcare expenses would lower and become more affordable for patients motivating them to pursue continuous treatment. With the freshly expanded consumer population, NASH market would experience an increased share in the global fatty liver disease therapeutics market.

Due to the trend shift in eating and working habits, added to the increasing inclination towards a luxurious lifestyle, incidences of fatty liver diseases has increased in numbers. Consumer segment of the Asia-Pacific region is expected to witness expansion inspiring higher market growth rate. NASH market stakeholders have definitive profits awaiting post-trial phase.

 

Related Post